Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis, page-53

  1. 13,454 Posts.
    lightbulb Created with Sketch. 7282
    Great to see tight hands today seems like SNT shareholders are valuing their holdings.
    Low Volume would indicate Holders are now realising the Parkinson Trial results are not far off to then be shortly followed by additional SNT 5505 data,,
    Hoping to see an increase in promotion from
    Gary to push company awareness prior to data plus now the Company has $21m in cash so I can’t see another CR to bridle the SP , looking forward to a run to take us firmly into double digits ,, NZT
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.8¢
Change
0.001(1.75%)
Mkt cap ! $94.23M
Open High Low Value Volume
5.6¢ 6.0¢ 5.6¢ $217.9K 3.795M

Buyers (Bids)

No. Vol. Price($)
2 272985 5.7¢
 

Sellers (Offers)

Price($) Vol. No.
5.8¢ 32000 1
View Market Depth
Last trade - 16.10pm 17/06/2025 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.